Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00693238 · ClinicalTrials.gov registry record · NA

Proton Therapy for Low and Intermediate Risk Prostate Cancer

A NA study of Prostate Cancer, sponsored by University of Florida.

Completed
Registry status
NA
Development phase
228
Enrollment target
1
Study location

NCT00693238 is a NA study of Prostate Cancer that has completed, run by University of Florida. The registered enrollment target is 228 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00693238, a NA study of Prostate Cancer, has completed, sponsored by University of Florida.

COMPLETED
Registry status
NA
Development phase
228 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to give a shorter course (5 ½ weeks) of radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of radiation, without decreasing the chance of killing prostate cancer cells.

Conditions Studied

Interventions

  • RADIATION Low Risk Proton Radiation
  • RADIATION Intermediate Risk Proton Radiation

Study Locations (1)

Florida

  • University of Florida Proton Therapy Institute - Jacksonville

Trial Details

FieldValue
Enrollment Target 228 participants
Start Date 2008-04
Est. Completion 2022-04-25
Phase NA

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT00693238

The ClinicalTrials.gov registry entry for NCT00693238 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (62% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Low Risk Proton Radiation is the first listed.

NCT00693238 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT00693238 about?

NCT00693238 is a clinical study titled "Proton Therapy for Low and Intermediate Risk Prostate Cancer". The purpose of this trial is to give a shorter course (5 ½ weeks) of radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of radiation, without decreasing the chance of killing prostate cancer cells.

What is the current status of trial NCT00693238?

This trial is currently completed. It is a NA study. The enrollment target is 228 participants. The study started on 2008-04. Estimated completion is 2022-04-25.

What conditions does trial NCT00693238 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00693238?

The interventions under investigation include: Low Risk Proton Radiation (RADIATION), Intermediate Risk Proton Radiation (RADIATION).

Who is sponsoring clinical trial NCT00693238?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00693238 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.